Weekly OHDSI Digest - 4Nov2019

MauraBeaton · November 4, 2019, 8:47pm

OHDSI MEETINGS THIS WEEK

OMOP CDM Oncology WG - Outreach/Research Subgroup Meeting - Tuesday at 10am ET
URL: https://zoom.us/j/780765541?pwd=RTVsRUVFdU4xV1BFZ2ZuVnJDVUVrdz09

The Book of OHDSI working group meeting - Tuesday at 11am ET
Zoom URL: https://columbiauniversity.zoom.us/j/258043190

Gold Standard Phenotype Library - Tuesday at 11am ET
URL: https://gatech.webex.com/webappng/sites/gatech/meeting/download/3d12d3ec89a34d568d8969fa5501e90b?siteurl=gatech&MTID=mdd4af3e9b84212fc7df3eb0150703df5

OHDSI Community Call - NO MEETING THIS WEEK

CDM Working Group - Tuesday at 1pm ET
URL: https://meet.lync.com/jnj-its/mblacke/V59RPVRY

OMOP CDM Oncology WG - Development Subgroup Meeting - Wednesday at 10 ET
URL: https://www.ohdsi.org/web/wiki/doku.php?id=documentation:oncology:development_schedule

ATLAS workgroup meeting - Wednesday at 10am ET
URL: https://jjconferencing.webex.com/webappng/sites/jjconferencing/meeting/info/129429150951851372?MTID=mca074ae1ff6eb7d80245d36b59188c80

Psychiatry Work Group - Thursday at 8am ET
URL: https://meet.lync.com/quintiles-quintilesims/sarah.seager/F0MS2T5B

Population-Level Estimation WG (Eastern Hemisphere) - Thursday at 3am ET
URL: https://meetings.webex.com/collabs/#/meetings/detail?uuid=M6WE9AOKFETH2VEFPVCZWWBIT0-D1JL&rnd=156731.38810

OMOP CDM Oncology WG - CDM/Vocabulary Subgroup Meeting - Thursday at 10am ET
URL: https://us04web.zoom.us/j/755053125?pwd=V0dOZVVnY3RMRWgxMVVGTDdVbnA1UT09

OMOP CDM Oncology WG - Genomic Subgroup Meeting - Friday at 10am ET
URL: https://us04web.zoom.us/j/412862164?pwd=NmpEWTdTQlB4N3VxT0tQRXdDWlg0dz09

EHR Work Group Meeting - Friday at 10am ET
URL: https://ucdenver.zoom.us/j/4984831362

China WG meeting - Friday at 10am
URL: https://global.gotomeeting.com/join/721873621

You can find a full list of upcoming OHDSI meetings here: https://docs.google.com/document/d/1X0oa9R-V8cwpF1WQZDJOqcXZguPKRiCZ6XrQ2zXMiuQ/edit

ANNOUNCEMENTS

OHDSI study published in Lancet! The LEGEND hypertension study been published in the Lancet! To check out the paper, click here:
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32317-7/fulltext
For more info on the study, check out our press release:
https://www.ohdsi.org/ohdsi-news-updates/legend-hypertension-study/

OHDSI Symposium Page - A full recap of the 2019 OHDSI U.S. Symposium, including photos, videos, collaborator showcase posters, and more, is available here https://www.ohdsi.org/2019-us-symposium-page/ . You can find it on the front page under the Symposium recap video, or as the first dropdown under the “2019 OHDSI Symposium” menu. Presentation slides are available there, and Symposium talks will begin to be posted this week, starting with the morning plenary session.

OHDSI Social Showcase We are posting one poster/demo/lightning talk from the Collaborator Showcase (#OHDSISocialShowcase) each weekday on both our Twitter and LinkedIn pages. Please check these out if you are on either, and share to promote all the great work OHDSI is doing. If you took part in the Collaborator Showcase, you’ll get an email on the Monday of the week you will be included to help you promote it.

2019 OHDSI Symposium - Videos Videos from the 2019 OHDSI symposium are being uploaded here: https://www.youtube.com/playlist?list=PLpzbqK7kvfeVWtDEc4VGmI1F_EBi_sJOF
A separate playlist for tutorials will be uploaded later this week.

Love is what you’ve been through with somebody.
James Thurber

COMMUNITY PUBLICATIONS

Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis.

ncbi.nlm.nih.gov

Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis.

MA Suchard, MJ Schuemie, HM Krumholz, SC You, R Chen, N Pratt, CG Reich, J Duke, D Madigan, G Hripcsak and PB Ryan, Lancet (London, England), Oct 24 2019

Uncertainty remains about the optimal monotherapy for hypertension, with current guidelines recommending any primary agent among the first-line drug classes thiazide or thiazide-like diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, dihydropyridine calcium channel blockers, and non-dihydropyridine calcium channel blockers, in the absence of comorbid indications. Randomised trials have not further refined this choice.We developed a comprehensive framework for real-world evidence that enables comparative effectiveness and safety evaluation across many drugs and outcomes from observational data encompassing millions of patients, while minimising inherent bias. Using this framework, we did a systematic, large-scale study under a new-user cohort design to estimate the relative risks of three primary (acute myocardial infarction, hospitalisation for heart failure, and stroke) and six secondary effectiveness and 46 safety outcomes comparing all first-line classes across a global network of six administrative claims and three electronic health record databases. The framework addressed residual confounding, publication bias, and p-hacking using large-scale propensity adjustment, a large set of control outcomes, and full disclosure of hypotheses tested.Using 4·9 million patients, we generated 22 000 calibrated, propensity-score-adjusted hazard ratios (HRs) comparing all classes and outcomes across databases. Most estimates revealed no effectiveness differences between classes; however, thiazide or thiazide-like diuretics showed better primary effectiveness than angiotensin-converting enzyme inhibitors: acute myocardial infarction (HR 0·84, 95% CI 0·75-0·95), hospitalisation for heart failure (0·83, 0·74-0·95), and stroke (0·83, 0·74-0·95) risk while on initial treatment. Safety profiles also favoured thiazide or thiazide-like diuretics over angiotensin-converting enzyme inhibitors. The non-dihydropyridine calcium channel blockers were significantly inferior to the other four classes.This comprehensive framework introduces a new way of doing observational health-care science at scale. The approach supports equivalence between drug classes for initiating monotherapy for hypertension-in keeping with current guidelines, with the exception of thiazide or thiazide-like diuretics superiority to angiotensin-converting enzyme inhibitors and the inferiority of non-dihydropyridine calcium channel blockers.US National Science Foundation, US National Institutes of Health, Janssen Research & Development, IQVIA, South Korean Ministry of Health & Welfare, Australian National Health and Medical Research Council.

Origins of the Arden Syntax.

ncbi.nlm.nih.gov

Origins of the Arden Syntax.

G Hripcsak, OB Wigertz and PD Clayton, Artificial intelligence in medicine, 2018 11

The Arden Syntax originated in the 1980's, when several knowledge-based systems began to show promise, but researchers recognized the burden of recreating these systems at every institution. Derived initially from Health Evaluation through Logical Processing (HELP) and the Regenstrief Medical Record System (RMRS), the Arden Syntax defines medical logic that can be encoded as independent rules, such as reminders and alerts, with the hope of creating a public library of rules. It was first vetted at an informatics retreat held in 1989 at Columbia University's Arden Homestead. The syntax was intended to be readable by clinician experts but to provide powerful array processing, which was derived largely a programming language called APL. The syntax was improved and implemented by a number of researchers and vendors in the early 1990's and was initially adopted by the consensus standards organization, the American Society for Testing and Materials.

Practical help for specifying the target difference in sample size calculations for RCTs: the DELTA2 five-stage study, including a workshop.
https://europepmc.org/abstract/med/31661431